Breed is associated with the ABCB1‐1Δ mutation in Australian dogs. Issue 3 (19th November 2019)

• Record Type: Journal Article
• Authors: Soussa, RW; Woodward, A; Marty, M; Cannon, CM
• Is Part Of: Australian veterinary journal. Volume 98:Issue 3(2020)
• Page Start: 79
• Page End: 83
• Publication Date: 2019-11-19
• Subjects: ABCB1 -- MDR1 -- mutation -- Australia -- breed -- veterinary oncology; Veterinary medicine -- Australia -- Periodicals; Veterinary medicine -- Periodicals; Veterinary Medicine -- Periodicals; 636.089
• DOI: 10.1111/avj.12896
• Languages: English
• ISSNs: 0005-0423

Abstract

Abstract : Objective: The ABCB1 gene encodes P‐glycoprotein (P‐gp), a cellular membrane pump. One functional mutation that leads to expression of a less functional form of P‐gp, ABCB1‐1Δ, has been described in dogs. Individuals with this mutation can have severe adverse reactions to common veterinary pharmaceuticals that are known substrates of this pump. We investigated the detection of this mutation in samples submitted to two Australian diagnostic laboratories. Methods: A total of 4842 dogs across 27 breeds were tested for the ABCB1‐1Δ mutation from buccal swabs or EDTA blood using standard PCR, multiplex PCR, or genotyping chip. Statistical analysis was applied to determine the proportions and odds ratios of the ABCB1‐1Δ mutation in herding breeds compared with non‐herding breeds. Results: The ABCB1‐1Δ mutation was detected in nine breeds. The most commonly affected breeds were collies, Australian shepherds, white Swiss shepherds, and Shetland sheepdogs. Of 32 dogs in 18 non‐herding breeds tested, one cocker spaniel and one labradoodle were positive for the mutation, both heterozygous. Conclusion: The most frequently affected breeds for ABCB1‐1Δ mutation are the collie, Australian shepherd, white Swiss shepherd and Shetland sheepdog. As the mutation is associated with an increased incidence of adverse reactions to commonly used pharmaceuticals, veterinarians need to be aware of the breeds at most risk of carrying this mutation and consider testing these individuals prior to administering these medications.